• 1
    Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol 2005; 58: 32337.
  • 2
    Polinski JM, Kilabuk E, Schneeweiss S, Brennan TA, Shrank WH. Changes in drug use and out-of-pocket costs associated with Medicare Part D implementation: a systematic review. J Am Geriatr Soc 2010; 58: 176479.
  • 3
    Sturmer T, Joshi M, Glynn RJ, Avorn J, Rothman KJ, Schneeweiss S. A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. J Clin Epidemiol 2006; 59: 43747.
  • 4
    Seeger JD, Walker AM, Williams PL, Saperia GM, Sacks FM. A propensity score-matched cohort study of the effect of statins, mainly fluvastatin, on the occurrence of acute myocardial infarction. Am J Cardiol 2003; 92: 144751.
  • 5
    Brookhart MA, Schneeweiss S, Rothman KJ, Glynn RJ, Avorn J, Sturmer T. Variable selection for propensity score models. Am J Epidemiol 2006; 163: 114956.
  • 6
    Glynn RJ, Schneeweiss S, Sturmer T. Indications for propensity scores and review of their use in pharmacoepidemiology. Basic Clin Pharmacol Toxicol 2006; 98: 2539.
  • 7
    Hirano K, Imbens GW. Estimation of causal effects using propensity score weighting: an application to data on right heart catheterization. Health Serv Outcomes Res Methodol 2001; 2: 25978.
  • 8
    Seeger JD, Kurth T, Walker AM. Use of propensity score technique to account for exposure-related covariates: an example and lesson. Med Care 2007; 45: S1438.
  • 9
    Schneeweiss S, Rassen JA, Glynn RJ, Avorn J, Mogun H, Brookhart MA. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiol 2009; 20: 51222.
  • 10
    Polinski JM, Shrank WH, Huskamp HA, Glynn RJ, Lieberman JN, Schneeweiss S. Changes in drug utilization during a gap in insurance coverage: an examination of the Medicare Part D coverage gap. PLoS Med 2011; 8: e1001075.
  • 11
  • 12
    High Dimensional Pharmacoepidemiology toolbox. 2011. (Accessed February 12, 2011, at
  • 13
    Schneeweiss S, Seeger JD, Maclure M, Wang PS, Avorn J, Glynn RJ. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol 2001; 154: 85464.
  • 14
    Rassen JA, Glynn RJ, Brookhart MA, Schneeweiss S. Observed performance of high-dimensional propensity score analyses of treatment effects in small samples. Am J Epidemiol 2011; 173: 140413.
  • 15
    Rosenbaum PR, Rubin DB. Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. Am Stat 1985; 39: 338.
  • 16
    Rubin DB, Thomas N. Matching using estimated propensity score: relating theory to practice. Biometrics 1996; 52: 24964.
  • 17
    Kurth T, Walker AM, Glynn RJ, et al. Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect. Am J Epidemiol 2006; 163: 26270.
  • 18
    Mahalanobis PC. On the generalized distance in statistics. Proc Natl Inst Sci India 1936; 12: 4955.
  • 19
    Cox DR. Regression models and life tables (with discussion). J R Stat Soc 1972; 34: 187220.
  • 20
    Hill J. Discussion of research using propensity-score matching: comments on ‘A critical appraisal of propensity-score matching in the medical literature between 1996 and 2003’ by Peter Austin, Statistics in Medicine. Statist Med 2008; 27: 205561; discussion 66–9.
  • 21
    Fitzmaurice G, Laird N, Ware J. Applied Longitudinal Analysis. John Wiley & Sons: Hoboken, NJ, 2004.
  • 22
    Rassen JA, Shelat AA, Myers J, Glynn RJ, Rothman KJ, Schneeweiss S. One-to-many propensity score matching in cohort studies. Pharmacoepidemiol Drug Saf 2012; 21(Suppl. 2): 6980.
  • 23
    Ho PM, Magid DJ, Shetterly SM, et al. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J 2008; 155: 7729.
  • 24
    Ho PM, Peterson ED, Wang L, et al. Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. JAMA 2008; 299: 5329.
  • 25
    Ho PM, Rumsfeld JS, Masoudi FA, et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med 2006; 166: 183641.
  • 26
    Ho PM, Spertus JA, Masoudi FA, et al. Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med 2006; 166: 18427.
  • 27
    Ho PM, Tsai TT, Wang TY, et al. Adverse events after stopping clopidogrel in post-acute coronary syndrome patients. Circ: Cardio Outcomes Qual 2010; 3: 3038.
  • 28
    Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA 2007; 297: 17786.
  • 29
    Beta-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction: II. Morbidity results. JAMA 1983; 250: 28149.
  • 30
    Psaty BM, Siscovick DS. Minimizing bias due to confounding by indication in comparative effectiveness research: the importance of restriction. JAMA 2010; 304: 8978.
  • 31
    Schneeweiss S, Patrick AR, Sturmer T, et al. Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial results. Med Care 2007; 45: S131-42.
  • 32
    Schneeweiss S. A basic study design for expedited safety signal evaluation based on electronic healthcare data. Pharmacoepidemiol Drug Saf 2010; 19: 85868.
  • 33
    Powers C. Beneficiary experience. Medicare Part D data symposium; October 30, 2008; Baltimore, MD: Centers for Medicare and Medicaid Services.